Creabilis Pharmaceuticals

Creabilis is a clinical-stage biopharmaceutical company specializing in the development of innovative topical treatments for severe dermatological diseases. The company's lead candidate, CT327 (now M5181), is a first-in-class topical TrkA kinase inhibitor designed to treat conditions such as atopic dermatitis and pruritus by targeting the nerve growth factor (NGF) pathway. Creabilis utilizes its proprietary Topical Drug Bio-Activation (TDBA) platform to create "soft drugs" that are active in the skin but rapidly degraded in the bloodstream to minimize systemic side effects. In 2016, the company was acquired by the Japanese pharmaceutical firm Maruho to strengthen its global dermatology pipeline.